×

Starpharma Holdings Limited

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP® drug delivery and VivaGel®.  Starpharma is developing VIRALEZE™, an antiviral nasal spray for COVID-19 which is complementary to vaccines and other preventative measures such as distancing and PPE. VIRALEZE™ also has potential use in future pandemics and is afforded expedited development because it is repurposing an already-marketed, broad-spectrum antiviral dendrimer, SPL7013. SPL7013 is utilised in approved  products – the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is approved in >40 countries and available in for sale in the UK, Europe, South East Asia, Australia and New Zealand.

As a leading company in dendrimer based drug delivery, Starpharma’s proprietary drug delivery platform technology, DEP®, which is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), and other world leading pharmaceutical companies Starpharma’s partnered DEP® programs have the potential to generate significant future milestones and royalties.

Founded in 1996, Starpharma listed on the Australian Securities Exchange in 2000 (ASX: SPL). Starpharma securities also trade in the US under the American Depository Receipts (ADR) program, and are listed on the OCTQX platform (OTCQX:SPHRY). OTCQX is the premium tier of the US Over-the-Counter (OTC) marketplace, providing non-US companies with a visible cross-listing to access US investors, without the duplicative regulatory costs required of listing on a traditional US exchange.

Spotlight Videos

News

Starpharma – The Next Big Australian Biotech

- by Greg Tolpigin

One of the main keys to maximizing returns from your capital is not just about riding a stock for its entire rally, it’s also about not committing capital during those periods when a stock is consolidating, resting or undergoing a lengthy consolidation. Look at virtually any stock and for at least 50% of the time there is actually no appreciation. Its typically two steps forward one step back – and that’s in the case of a share price in an actual long-term uptrend.

Read More